- Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
- Relief Therapeutics Expands U.S. Commercial Team
- Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
- Relief Therapeutics to Participate in Industry and Investor Conferences in May
- Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
- Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
- Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
- Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
- Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
- Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
More ▼
Key statistics
On Wednesday, Relief Therapeutics Holding SA (RLF:SWX) closed at 0.0566, 20.43% above the 52 week low of 0.047 set on Apr 29, 2022.
52-week range
Markit short selling activity
Open | 0.055 |
---|---|
High | 0.0579 |
Low | 0.0549 |
Bid | 0.0552 |
Offer | 0.057 |
Previous close | 0.0542 |
Average volume | 6.34m |
---|---|
Shares outstanding | 4.41bn |
Free float | 2.96bn |
P/E (TTM) | -- |
Market cap | 249.79m CHF |
EPS (TTM) | -0.0096 CHF |
Data delayed at least 15 minutes, as of May 25 2022 16:39 BST.
More ▼